Literature DB >> 11302568

Atypical antipsychotics in bipolar and schizoaffective disorders.

E S Brown1, N R Thomas, T Carmody, S Mahadi, V A Nejtek.   

Abstract

No data are available comparing the relative efficacy of different atypical agents in patients with bipolar disorder. A chart review of bipolar and schizoaffective disorder patients who had received courses of at least two atypical agents (n = 33) in a community psychiatry system was conducted. No differences in rates of hospitalizations were found between individual atypical agents or between atypical agents as a class and conventional neuroleptics. However, a significant reduction in rates of emergency room visits was found with atypical agents compared to conventional neuroleptics, with a trend toward greater reduction with clozapine compared to other atypical antipsychotics. Larger prospective studies are needed to confirm these preliminary observations.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11302568     DOI: 10.1055/s-2001-15179

Source DB:  PubMed          Journal:  Pharmacopsychiatry        ISSN: 0176-3679            Impact factor:   5.788


  4 in total

1.  Low doses of clozapine may stabilize treatment-resistant bipolar patients.

Authors:  Bettina S Fehr; M Erkan Ozcan; Trisha Suppes
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2004-11-12       Impact factor: 5.270

Review 2.  Olanzapine: a review of its use in the treatment of bipolar I disorder.

Authors:  N Bhana; C M Perry
Journal:  CNS Drugs       Date:  2001       Impact factor: 5.749

Review 3.  The bipolar patient with comorbid substance use disorder: recognition and management.

Authors:  Mark J Albanese; Ronald Pies
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

Review 4.  Acute and long-term treatment of mania.

Authors:  Eduard Vieta; Jose Sanchez-Moreno
Journal:  Dialogues Clin Neurosci       Date:  2008       Impact factor: 5.986

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.